Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ #GVHD–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The hybrid meeting
Click here to view original post